Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tipifarnib - Kura Oncology

Next Previous
X
Search
Drug Profile

Tipifarnib - Kura Oncology

Alternative Names: NSC-702818; R-115777; Zarnestra

Latest Information Update: 28 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen L.P.; Janssen-Cilag; Johnson & Johnson
  • Developer Emory University; H. Lee Moffitt Cancer Center and Research Institute; Janssen-Cilag; Johnson & Johnson; Kura Oncology; National Cancer Institute (USA); Samsung Medical Center; Spanish Lung Cancer Group; University of Texas M. D. Anderson Cancer Center
  • Class Amines; Antineoplastics; Cardiovascular therapies; Chlorobenzenes; Imidazoles; Ketones; Quinolines; Small molecules
  • Mechanism of Action Farnesyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Acute myeloid leukaemia; T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Pancreatic cancer
  • Phase II Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Non-small cell lung cancer; Peripheral T-cell lymphoma; Squamous cell cancer; Thyroid cancer; Urogenital cancer
  • Phase I/II Multiple myeloma
  • Preclinical Hypertrophic cardiomyopathy; Renal cell carcinoma
  • No development reported Cutaneous T-cell lymphoma; Rhabdomyosarcoma; Solid tumours
  • Discontinued Breast cancer; Glioblastoma

Most Recent Events

  • 28 Nov 2024 No recent reports of development identified for preclinical development in Rhabdomyosarcoma in USA
  • 28 Jun 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (PO)
  • 05 Apr 2024 Pharmacodynamics data from preclinical studies in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top